Impacts of delta and omicron variants on inactivated SARS‐CoV‐2 vaccine‐induced T cell responses in patients with autoimmune diseases and healthy controls

Abstract

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection causes coronavirus disease 2019 (COVID‐19), which is still devastating economies and communities globally. The increasing infections of variants of concern (VOCs) in vaccinated population have raised concerns about the effectiveness of current vaccines. Patients with autoimmune diseases (PAD) under immunosuppressant treatments are facing higher risk of infection and potentially lower immune responses to SARS‐CoV‐2 vaccination. Methods Blood samples were collected from PAD or healthy controls (HC) who finished two or three doses of inactivated vaccines. Spike peptides derived from wild‐type strain, delta, omicron BA.1 were utilised to evaluate T cell responses and their cross‐recognition of delta and omicron in HC and PAD by flow cytometry and ex vivo IFNγ‐ELISpot. Results We found that inactivated vaccine‐induced spike‐specific memory T cells were long‐lasting in both PAD and HC. These spike‐specific T cells were highly conserved and cross‐recognized delta and omicron. Moreover, a third inactivated vaccine expanded spike‐specific T cells that responded to delta and omicron spike peptides substantially in both PAD and HC. Importantly, the polyfunctionality of spike‐specific memory T cells was preserved in terms of cytokine and cytotoxic responses. Although the extent of T cell responses was lower in PAD after two‐dose, T cell responses were boosted to a greater magnitude in PAD by the third dose, bringing comparable spike‐specific T cell immunity after the third dose. Conclusion Inactivated vaccine‐induced spike‐specific T cells remain largely intact against delta and omicron variants. This study expands our understanding of inactivated vaccine‐induced T cell responses in PAD and HC, which could have important indications for vaccination strategy.

Keywords

• cross‐recognition
• delta variant
• inactivated SARS‐CoV‐2 vaccine
• omicron variant
• spike‐specific T cell responses